

TABLE 1. The Anticonvulsive Activity of Compounds I and II

Compound	LD ₅₀ , mg/kg	Therapeutic ratio (LD ₅₀ /ED ₅₀)	Dose, mg/kg	Maximum electric shock test			Convulsive threshold of Corazol, mg/kg	
				prevention of convulsions, %	surviving animals, %	ED ₅₀ , mg/kg	<i>M ± m. p</i>	ACI
I	2000	22,2	200	50,0	100	90	112,9 ± 3,5 0,192	1,10
			100	50,0	100			
			50	16,7	100			
II	2000	22,2	200	80,0	100	90	135,0 ± 7,8 0,008	1,30
			100	50,0	66,7			
			50	16,7	100			
Chloracon	1368	5,7	200	50,0	83,3	240	132,4 ± 11,4 0,025	1,30
			400	66,7	100			
			100	16,7	83,3			

Notes: ACI = anti-Corazol index

TABLE 2. The Antihypoxic Activity of Compounds I and II

Compound	Dose, mg/kg	Sodium nitrite, 300 mg/kg			Sodium nitroprusside, 25 mg/kg			Barochamber		
		control	experiment	AHI	control	experiment	AHI	control	experiment	AHI
I	200	18,2 ± 0,9	18,5 ± 1,7 0,845	1,0	13,8 ± 1,2	16,0 ± 0,9 0,141	1,2	33,0 ± 2,2	41,0 ± 2,3 0,034	1,3
II	200	18,2 ± 0,9	17,0 ± 0,9 0,389	0,9	13,8 ± 1,2	13,7 ± 1,2 0,922	0,99	35,5 ± 2,1	40,5 ± 2,4 0,141	1,14

Notes: AHI = antihypoxic index

In the Corazol titration test, benzhydrylureas I and II had weak anticonvulsive activity, though the trifluoroacetyl derivative II significantly increased the convulsive threshold of Corazol. However, in the maximum electric shock test, compounds I and II had similar high levels of anticonvulsive activity, with ED₅₀ = 90 mg/kg; activity was almost three times greater than that of the reference agent Chloracon (ED₅₀ = 240 mg/kg). Therapeutic ratios were correspondingly wider than that of the reference compound (see Table 1). In addition, it must be mentioned that benzhydrylureas I and II were significantly less active than the unsubstituted benzhydrylurea, which had EC₅₀ = 47 mg/kg and an anti-Corazol index of 3.7 [2]. Both compounds had weak antihypoxic activity in models of acute hypoxia (see Table 2), and were less active than the unsubstituted benzhydrylurea [3].

Thus, the new benzhydrylureas I and II had pronounced anticonvulsive activity in the maximum electric shock test, but had low activity as antihypoxic agents.

EXPERIMENTAL (CHEMICAL)

IR spectra were recorded using a UR-20 apparatus. PMR spectra were taken on a Tesla BS-497 spectrometer (using HMDE as the internal standard, at 100 MHz). Reactions were followed and product purity was confirmed by TLC analysis on Silufol UV-254 plates, eluted with benzene:ethanol (8:2), and spots were detected in UV light. Elemental analyses agreed with expected values.

2-Hydroxyl-5-chlorobenzhydrylurea (I). 2-Hydroxyl-5-chlorobenzhydrylurea (0.01 mol) was heated with nitrourea (0.015 mol) in 100 ml of water for 5 h at 70°C. The reaction mix was cooled, and the resulting precipitate was washed with warm water and recrystallized from ethanol; this produced the desired product, compound I, with a yield of 72%. The melting temperature was 203-205°C and the formula was C₁₄H₁₃ClN₂O₂. The IR spectrum (vaseline, ν_{\max} , cm⁻¹) was: 1670 (CO), 3343 (NH), 3460, 3420 (NH₂), 3580 (OH). The PMR spectrum (δ , DMSO-d₆, ppm) was: 5.95 s (NH₂), 6.04 (1H, CH), 6.88 (1H, NH), 7.66-8.22 m (8H, aromatic).

N-(2-Hydroxyl-5-chlorobenzhydryl)-N'-(trifluoroacetyl)urea (II). 2-Hydroxyl-5-chlorobenzhydrylurea I (0.01 mol) was mixed with 0.02 mol of freshly prepared trifluoroacetic anhydride in 20 ml of anhydrous benzene in the presence of 2 drops of sulfuric acid ($d = 1.84$) for 1 h. The solvent was then evaporated, and the resulting precipitate was recrystallized from

hexane, to produce compound II with a yield of 80%. The melting temperature was 313-314°C, and the formula was $C_{16}H_{12}ClN_2O_3F_3$. The IR spectrum (vaseline, ν_{\max} , cm^{-1}) was: 1685 (C=O), 1710 (COCF₃), 3350 (NH), 3215 (CONHCO). The PMR spectrum (δ , DMSO- d_6 , ppm) was: 6.08 (1H, CH), 8.72 (1H, NH), 7.68-8.35 m (8H, aromatic), 10.75 s (1H, NH).

REFERENCES

1. A. A. Bakibaev, V. K. Gorshkova, L. G. Tignibidina, et al., *Khim. Farm. Zh.*, No 3, 28 (1993).
2. V. D. Filimonov, A. A. Bakibaev, A. V. Pustovoitov, et al., *Khim. Farm. Zh.*, No 5, 540-545 (1988).
3. A. G. Pechenin, L. G. Tignibidina, V. K. Gorshkova, et al., *Khim. Farm. Zh.*, No 5, 57-59 (1979).
4. A. A. Bakibaev, V. D. Filimonov, L. G. Tignibidina, et al., *Khim. Farm. Zh.*, No 4, 34 (1993).
5. A. H. Amin, D. R. Metha, and S. S. Samarth, *Drug Res.*, 14, 218-268 (1970).
6. S. A. Andronati and T. A. Voronina, *The Directed Search for New Neurotropic Preparations* [in Russian], Riga (1983), pp. 94-109.
7. G. Resnati, *Farmaco*, 45, No. 11, 1137-1167 (1990).
8. M. G. Vigorita, T. Previtera, and C. Zappala, *Farmaco*, 45, No. 2, 225-235 (1990).